北京大学学报(医学版) ›› 2025, Vol. 57 ›› Issue (2): 388-392. doi: 10.19723/j.issn.1671-167X.2025.02.026

• 病例报告 • 上一篇    下一篇

双膦酸盐相关性颌骨坏死1例

杨菊1,2, 刘玥3, 曲春娜4, 孙健斌5, 李天英6, 石连杰2,7,△()   

  1. 1. 遂宁市中心医院风湿免疫科,四川遂宁 629099
    2. 北京大学国际医院风湿免疫科,北京 102206
    3. 北京大学国际医院口腔颌面外科,北京 102206
    4. 北京大学国际医院口腔科,北京 102206
    5. 北京大学国际医院内分泌科,北京 102206
    6. 北京大学国际医院病理科,北京 102206
    7. 北京大学首钢医院风湿免疫科,北京 100144
  • 收稿日期:2022-04-22 出版日期:2025-04-18 发布日期:2025-04-12
  • 通讯作者: 石连杰 E-mail:shilianjie1999@163.com
  • 基金资助:
    北京大学国际医院院内基金重点项目(YN2020ZD01)

Bisphosphonates-related osteonecrosis of the jaw: A case report

Ju YANG1,2, Yue LIU3, Chunna QU4, Jianbin SUN5, Tianying LI6, Lianjie SHI2,7,△()   

  1. 1. Department of Rheumatology and Immunology, Suining Central Hospital, Suining 629099, Sichuan, China
    2. Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China
    3. Department of Maxillofacial Surgery, Peking University International Hospital, Beijing 102206, China
    4. Department of Stomatology, Peking University International Hospital, Beijing 102206, China
    5. Department of Endocrinology, Peking University International Hospital, Beijing 102206, China
    6. Department of Pathology, Peking University International Hospital, Beijing 102206, China
    7. Department of Rheumatology and Immunology, Peking University Shougang Hospital, Beijing 100144, China
  • Received:2022-04-22 Online:2025-04-18 Published:2025-04-12
  • Contact: Lianjie SHI E-mail:shilianjie1999@163.com
  • Supported by:
    Peking University International Hospital Research Funds(YN2020ZD01)

RICH HTML

  

关键词: 双膦酸盐相关性颌骨坏死, 骨质疏松, 唑来膦酸

Abstract:

Osteonecrosis of the mandible is also called avascular necrosis of the jaw, and it is a rare complication of bisphosphonates. It is characterized with pain, swelling, exposure of bone, local infection and pathologic fractures of the jaw. With the widespread usage of bisphosphonates in bone metastasis of malignant tumors and osteoporosis, this rare complication has received more attention in recent years. Here, we reported a case of bisphosphonates-related osteonecrosis of the jaw (BRONJ) caused by intravenous zoledronic acid for osteoporosis. A 62-year-old female patient with 7-year history of Sjögren's syndrome and 3-year history of osteoporosis developed BRONJ after 3-year treatment of zoledronic acid. Two months before she went to the Peking University International Hospital, she visited the dentist for periodontal purulent secretion and extracted one tooth from the right mandible. However, the condition was not improved and she felt persistent pain and swelling in the right mandible. Hence, she received repeated root curettage, but there was no improvement. Finally, she was diagnosed with osteonecrosis of the mandible based on the digital volume tomography scan, which showed right mandibular osteonecrosis bone destruction. She underwent surgical debridement of the necrotic bone and administered intravenous antibio-tics at the Peking University International Hospital. Histopathological analysis of the bone biopsy further confirmed the diagnosis of BRONJ. Her condition was improved successfully during a 3-year follow-up. Osteonecrosis of the mandible become more common with the increased use of bisphosphonates. Recent study has reported that osteonecrosis of the mandible is more likely to occur in patients with Sjögren's syndrome. In addition, age, long-term and irregular administration of glucocorticoids, irregular oral examination and treatment also might be the risk factors in the pathogenesis of osteonecrosis of the mandible. For the elder osteoporosis patients who would receive or had received bisphosphonate-related drugs, oral health status and the disease states associated with necrosis of the mandible such as Sjögren's syndrome should be comprehensively measured and fully evaluated during the whole process. Furthermore, to better understand and prevent or reduce the occurrence of this complication, we reviewed the patho-genesis, diagnosis, treatment, and prevention of BRONJ.

Key words: Bisphosphonate-associated osteonecrosis of the jaw, Osteoporosis, Zoledronic acid

中图分类号: 

  • R782.32

图1

下颌骨坏死术前术后X线下表现"

图2

术后下颌黏膜组织及少量骨组织病理学检查结果(HE×200)"

1 Fleisch H . Biphosphonate as a therapeutic drug: Experimental studies and clinical application[J]. Ther Umsch, 1985, 42 (6): 366- 375.
2 Haraguchi R , Kitazawa R , Mori K , et al. sFRP4-dependent Wnt signal modulation is critical for bone remodeling during postnatal development and age-related bone loss[J]. Sci Rep, 2016, 6, 25198.
doi: 10.1038/srep25198
3 Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61 (9): 1115- 1117.
doi: 10.1016/S0278-2391(03)00720-1
4 Everts-Graber J , Lehmann D , Burkard JP , et al. Risk of osteo-necrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis[J]. J Bone Miner Res, 2021, 37 (2): 340- 348.
5 朱洁云, 高敏, 宋秋韵, 等. 中国老年人骨质疏松症患病率的Meta分析[J]. 中国全科医学, 2022, 25 (3): 346- 353.
6 Black DM , Rosen CJ . Clinical practice. Postmenopausal psteoporosis[J]. N Engl J Med, 2016, 374 (3): 254- 262.
doi: 10.1056/NEJMcp1513724
7 Kuo PI , Lin TM , Chang YS , et al. Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw[J]. Sci Rep, 2021, 11 (1): 1612.
doi: 10.1038/s41598-020-80622-5
8 Allen MR , Burr DB . Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment[J]. J Oral Maxillofac Surg, 2008, 66 (5): 987- 994.
doi: 10.1016/j.joms.2008.01.038
9 郎淼杰, 周稚辉, 毛静静, 等. 唑来膦酸对血管内皮细胞损伤的影响[J]. 中华口腔医学杂志, 2015, 50 (7): 399- 402.
10 Taniguchi N , Osaki M , Onuma K , et al. Bisphosphonate-induced reactive oxygen species inhibit proliferation and migration of oral fibroblasts: A pathogenesis of bisphosphonate-related osteonecrosis of the jaw[J]. J Periodontol, 2020, 91 (7): 947- 955.
doi: 10.1002/JPER.19-0385
11 Marx RE , Cillo JE Jr , Ulloa JJ . Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment[J]. J Oral Maxillofac Surg, 2007, 65 (12): 2397- 2410.
doi: 10.1016/j.joms.2007.08.003
12 Koneski F , Popovic-Monevska D , Gjorgoski I , et al. In vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws[J]. J Craniomaxillofac Surg, 2018, 46 (2): 230- 236.
13 Kizub DA , Miao J , Schubert MM , et al. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)[J]. Support Care Cancer, 2021, 29 (5): 2509- 2517.
14 Ruggiero SL , Dodson TB , Assael LA , et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw: 2009 update[J]. Aust Endod J, 2009, 35 (3): 119- 130.
15 吴平凡, 李羽, 雷振革, 等. 种植体引起双膦酸盐相关性下颌骨坏死1例[J]. 华西口腔医学杂志, 2020, 38 (4): 460- 463.
16 Adler RA , El-Hajj Fuleihan G , Bauer DC , et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research[J]. J Bone Miner Res, 2016, 31 (1): 16- 35.
17 He L , Sun X , Liu Z , et al. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw[J]. Int J Oral Sci, 2020, 12 (1): 30.
18 Yu W , Su J . The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice[J]. Oral Dis, 2020, 26 (3): 609- 620.
19 Ruggiero SL , Dodson TB , Fantasia J , et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update[J]. J Oral Maxillofac Surg, 2014, 72 (10): 1938- 1956.
20 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10 (5): 413- 443.
21 Watts NB , Diab DL . Long-term use of bisphosphonates in osteoporosis[J]. J Clin Endocrinol Metab, 2010, 95 (4): 1555- 1565.
[1] 盛春辉, 张晓, 吕珑薇, 周永胜. 人脂肪间充质干细胞外泌体对去势小鼠骨质疏松的预防[J]. 北京大学学报(医学版), 2025, 57(2): 217-226.
[2] 白心竹,何金徽,陆松松,李春,王依林,熊建. 椎体骨折合并活化部分凝血活酶时间延长1例[J]. 北京大学学报(医学版), 2024, 56(2): 371-374.
[3] 汪大伟,王华东,李利,尹欣,黄伟,郭继东,杨亚锋,刘义灏,郑扬. 自体下关节突骨块应用于骨质疏松患者腰椎椎间融合术的疗效分析[J]. 北京大学学报(医学版), 2023, 55(5): 899-909.
[4] 姜保国,张培训. 老年髋部骨折的围手术期风险评估[J]. 北京大学学报(医学版), 2022, 54(5): 803-809.
[5] 王鹏,吴华,车颖,范东伟,刘珏,陶立元. 亚洲骨质疏松筛查工具在健康体检中的筛查准确性评价及适宜切点研究[J]. 北京大学学报(医学版), 2019, 51(6): 1085-1090.
[6] 朱洁,李建红,袁婷婷,和璐,梁宇红. 绝经期妇女牙周状况与骨质密度的相关性分析[J]. 北京大学学报(医学版), 2019, 51(6): 1115-1118.
[7] 孙浩林,李淳德,李绪文,邑晓东,刘洪,卢海霖,李宏,于峥嵘,王宇. 多孔中空椎弓根螺钉骨水泥加强固定治疗合并骨质疏松症的腰椎退变性侧凸[J]. 北京大学学报(医学版), 2017, 49(2): 256-261.
[8] 商澜镨,田耘,刘晓光. 聚甲基丙烯酸甲酯与可吸收骨水泥治疗骨质疏松椎体压缩骨折的临床疗效对照研究[J]. 北京大学学报(医学版), 2017, 49(2): 267-273.
[9] 孙浩林,李淳德,杨泽川,邑晓东,刘洪,卢海霖,李宏,王宇. 多孔中空椎弓根螺钉骨水泥加强固定治疗合并骨质疏松症的腰椎退变性疾病[J]. 北京大学学报(医学版), 2016, 48(6): 1019-1025.
[10] 王翯,胡肇衡,陈玲,潘宇. 口服双膦酸盐用药史对静脉注射唑来膦酸治疗骨质疏松发热不良反应的影响[J]. 北京大学学报(医学版), 2016, 48(4): 680-682.
[11] 韦祎,田伟,刘波,行勇刚,王永庆,崔冠宇. 绝经后骨质疏松女性椎体楔形变的影像学测量[J]. 北京大学学报(医学版), 2016, 48(3): 568-封三.
[12] 李宁,刘昊楠,龚晓峰,朱仕文,吴新宝,贺良. 北京某三甲医院股骨颈骨折住院患者现状的流行病学分析[J]. 北京大学学报(医学版), 2016, 48(2): 292-296.
[13] 王昱,郝燕捷,邓雪蓉,李光韬,耿研,赵娟,周炜,张卓莉. 类风湿关节炎患者骨量改变危险因素分析及FRAX的应用价值[J]. 北京大学学报(医学版), 2015, 47(5): 781-786.
[14] 孙浩林, 李淳德, 朱佳琳, 邑晓东, 刘洪, 卢海霖, 李宏, 于峥嵘, 王宇. PVP或PKP治疗激素诱导骨质疏松性椎体压缩骨折的临床研究[J]. 北京大学学报(医学版), 2015, 47(2): 242-247.
[15] 黄天霁, 寇玉辉, 殷晓峰, 熊建, 张培训, 张殿英, 付中国, 薛峰, 姜保国. 椎体强化术后再发椎体骨折的临床特点和危险因素[J]. 北京大学学报(医学版), 2015, 47(2): 237-241.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!